3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
69
Carcinoma, Intraductal, Noninfiltrating
9
Breast Carcinoma In Situ
6
Breast Neoplasms, Male
5
Neoplasms
3
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
2
Inflammatory Breast Neoplasms
2
Sleep Wake Disorders
1
Risk Reduction Behavior
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Obesity
1
Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer
1
Mastodynia
1
Glioma
1
Fibrocystic Breast Disease
1
Fibroadenoma
1
Fatigue
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Disease Progression
1
Desmoid Tumors
1
Cystic Fibrosis
1
Cystadenocarcinoma, Serous
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Lobular
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Cancer Metastatic
1
Interventions
3-Iodobenzylguanidine
3
cabozantinib
2
tipifarnib
1
pembrolizumab
1
pazopanib
1
lutetium Lu 177 dotatate
1
lenvatinib
1
guadecitabine
1
fostamatinib
1
copper dotatate CU-64
1
atezolizumab
1
Temozolomide
1
Surgical Procedures, Operative
1
Sunitinib
1
Phenoxybenzamine
1
Nivolumab
1
Lutetium-177
1
Lutetium
1
Iodine-131
1
Everolimus
1
Erlotinib Hydrochloride
1
Doxazosin
1
Capecitabine
1
Axitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Pheochromocytoma
×
Tamoxifen
×
Clear all
No trials found.